Opioids and the skin - Where do we stand?

Experimental Dermatology

Volumn 18, Issue 5, 2009, Pages 424-430

  Bigliardi, Paul L ^a   Tobin, Desmond J ^b   Gaveriaux Ruff, Claire ^c   Bigliardi Qi, Mei ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF BRADFORD   (United Kingdom)

^c UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

Differentiation; Immune system; Melanocytes; Opioids; Pruritus; Skin

Indexed keywords

BETA ENDORPHIN; CYTOKERATIN 16; DELTA OPIATE RECEPTOR; DYNORPHIN; ENDORPHIN DERIVATIVE; ENKEPHALIN DERIVATIVE; KAPPA OPIATE RECEPTOR; MESSENGER RNA; MU OPIATE RECEPTOR; OPIATE PEPTIDE; OPIATE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2;

APOPTOSIS; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CYTOKINE PRODUCTION; DOWN REGULATION; EPIDERMIS; GENE ACTIVATION; GENE EXPRESSION REGULATION; HAIR FOLLICLE; HUMAN; IMMUNOCOMPETENT CELL; KERATINOCYTE; LYMPHOCYTE PROLIFERATION; MELANOCYTE; MELANOGENESIS; NONHUMAN; PERIPHERAL NERVOUS SYSTEM; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; SEBACEOUS GLAND; SIGNAL TRANSDUCTION; SKIN STRUCTURE; T LYMPHOCYTE; UPREGULATION; VITILIGO;

ANALGESICS, OPIOID; ANIMALS; CELL DIFFERENTIATION; GENE EXPRESSION REGULATION; HUMANS; IMMUNE SYSTEM; LIGANDS; MELANOCYTES; MICE; PRURITUS; RECEPTORS, OPIOID; RNA, MESSENGER; SKIN; SKIN PHYSIOLOGICAL PHENOMENA;

EID: 65249154034     PISSN: 09066705     EISSN: 16000625     Source Type: Journal    
DOI: 10.1111/j.1600-0625.2009.00844.x     Document Type: Review

References (72)

1. Zhang G, Mohammad H, Peper B D, Raja S, Wilson S P, Sweitzer S M. Enhanced peripheral analgesia using virally mediated gene transfer of the mu-opioid receptor in mice. Anesthesiology 2008: 108: 305-313.
2. Bigliardi-Qi M, Lipp B, Sumanovski L T, Buechner S A, Bigliardi P L. Changes of epidermal mu-opiate receptor expression and nerve endings in chronic atopic dermatitis. Dermatology 2005: 210: 91-99.
3. Stander S, Gunzer M, Metze D, Luger T, Steinhoff M. Localization of micro-opioid receptor 1A on sensory nerve fibers in human skin. Regul Pept 2002: 110: 75-83.
4. Bigliardi P L, Bigliardi-Qi M, Buechner S, Rufli T. Expression of mu-opiate receptor in human epidermis and keratinocytes. J Invest Dermatol 1998: 111: 297-301.
5. Tominaga M, Ogawa H, Takamori K. Possible roles of epidermal opioid systems in pruritus of atopic dermatitis. J Invest Dermatol 2007: 127: 2228-2235.
6. Bigliardi-Qi M, Gaveriaux-Ruff C, Pfaltz K et al. Deletion of mu- and kappa-opioid receptors in mice changes epidermal hypertrophy, density of peripheral nerve endings, and itch behavior. J Invest Dermatol 2007: 127: 1479-1488.
7. Bigliardi-Qi M, Gaveriaux-Ruff C, Zhou H et al. Deletion of delta-opioid receptor in mice alters skin differentiation and delays wound healing. Differentiation 2006: 74: 174-185.
8. Kauser S, Schallreuter K U, Thody A J, Gummer C, Tobin D J. Regulation of human epidermal melanocyte biology by beta-endorphin. J Invest Dermatol 2003: 120: 1073-1080.
9. Tobin D J, Kauser S. Beta-endorphin: The forgotten hair follicle melanotropin. J Investig Dermatol Symp Proc 2005: 10: 212-216.
10. Tobin D J, Kauser S. Hair melanocytes as neuro-endocrine sensors-pigments for our imagination. Mol Cell Endocrinol 2005: 243: 1-11.
11. Kauser S, Thody A J, Schallreuter K U, Gummer C L, Tobin D J. beta-Endorphin as a regulator of human hair follicle melanocyte biology. J Invest Dermatol 2004: 123: 184-195.
12. Hosoi J, Ozawa H, Granstein R D. beta-Endorphin binding and regulation of cytokine expression in Langerhans cells. Ann N Y Acad Sci 1999: 885: 405-413.
13. Kirst A, Wack C, Lutz W K, Eggert A, Kampgen E, Fischer W H. Expression of functional kappa-opioid receptors on murine dendritic cells. Immunol Lett 2002: 84: 41-48.
14. Rittner H L, Brack A, Stein C. Pain and the immune system. Br J Anaesth 2008: 101: 40-44.
15. Rittner H L, Brack A, Stein C. The other side of the medal: How chemokines promote analgesia. Neurosci Lett 2008: 437: 203-208.
16. Kieffer B L, Gaveriaux-Ruff C. Exploring the opioid system by gene knockout. Prog Neurobiol 2002: 66: 285-306.
17. Wintzen M, de Winter S, Out-Luiting J J, van Duinen S G, Vermeer B J. Presence of immunoreactive beta-endorphin in human skin. Exp Dermatol 2001: 10: 305-311.
18. Nissen J B, Kragballe K. Enkephalins modulate differentiation of normal human keratinocytes in vitro. Exp Dermatol 1997: 6: 222-229.
19. Tachibana T, Nawa T. Immunohistochemical reactions of receptors to met-enkephalin, VIP, substance P, and CGRP located on Merkel cells in the rat sinus hair follicle. Arch Histol Cytol 2005: 68: 383-391.
20. Schulze E, Witt M, Fink T, Hofer A, Funk R H. Immunohistochemical detection of human skin nerve fibers. Acta Histochem 1997: 99: 301-309.
21. Zagon I S, Wu Y, McLaughlin P J. The opioid growth factor, [Met5]-enkephalin, and the zeta opioid receptor are present in human and mouse skin and tonically act to inhibit DNA synthesis in the epidermis. J Invest Dermatol 1996: 106: 490-497.
22. Salemi S, Aeschlimann A, Wollina U et al. Up-regulation of delta-opioid receptors and kappa-opioid receptors in the skin of fibromyalgia patients. Arthritis Rheum 2007: 56: 2464-2466.
23. Bodnar R J. Endogenous opiates and behavior: 2006. Peptides 2007: 28: 2435-2513.
24. Bigliardi-Qi M, Bigliardi P L, Eberle A N, Buchner S, Rufli T. beta-endorphin stimulates cytokeratin 16 expression and downregulates mu-opiate receptor expression in human epidermis. J Invest Dermatol 2000: 114: 527-532.
25. Bigliardi P L, Buchner S, Rufli T, Bigliardi-Qi M. Specific stimulation of migration of human keratinocytes by mu-opiate receptor agonists. J Recept Signal Transduct Res 2002: 22: 191-199.
26. Bigliardi-Qi M, Bigliardi P L, Buchner S, Rufli T. Characterization of mu-opiate receptor in human epidermis and keratinocytes. Ann N Y Acad Sci 1999: 885: 368-371.
27. Bigliardi P L, Sumanovski L T, Buchner S, Rufli T, Bigliardi-Qi M. Different expression of mu-opiate receptor in chronic and acute wounds and the effect of beta-endorphin on transforming growth factor beta type II receptor and cytokeratin 16 expression. J Invest Dermatol 2003: 120: 145-152.
28. Poonawala T, Levay-Young B K, Hebbel R P, Gupta K. Opioids heal ischemic wounds in the rat. Wound Repair Regen 2005: 13: 165-174.
29. Rook J M, Hasan W, McCarson K E. Temporal effects of topical morphine application on cutaneous wound healing. Anesthesiology 2008: 109: 130-136.
30. Cheng B, Liu H W, Fu X B, Sheng Z Y, Li J F. Coexistence and upregulation of three types of opioid receptors, mu, delta and kappa, in human hypertrophic scars. Br J Dermatol 2008: 158: 713-720.
31. Zagon I S, Verderame M F, McLaughlin P J. The biology of the opioid growth factor receptor (OGFr). Brain Res Brain Res Rev 2002: 38: 351-376.
32. Tobin D J. Biochemistry of human skin-our brain on the outside. Chem Soc Rev 2006: 35: 52-67.
33. Stein C, Ahmed H S, Hassan F. Opioids from immunocytes interact with receptors on sensory nerves to inhibit nocireception in inflammation. Proc Natl Acad Sci USA 1990: 87: 5935-5939.
34. Coggeshall R E, Zhou S, Carlton S M. Opioid receptors on peripheral sensory axons. Brain Res 1997: 764: 126-132.
35. Zylka M J, Rice F L, Anderson D J. Topographically distinct epidermal nociceptive circuits revealed by axonal tracers targeted to Mrgprd. Neuron 2005: 45: 17-25.
36. Lumpkin E A, Caterina M J. Mechanisms of sensory transduction in the skin. Nature 2007: 445: 858-865.
37. Bigliardi P L, Bigliardi-Qi M. Peripheral Opiate Receptor System in Human Epidermis and Itch. In: Yosipovitch G, Greaves M W, Fleischer A B Jr, McGlone F, eds. Itch: Basic Mechanisms and Therapy. New York: Marcel Dekker, Inc., 2004: 97-106.
38. Bigliardi P L, Stammer H, Jost G, Rufli T, Buchner S, Bigliardi-Qi M. Treatment of pruritus with topically applied opiate receptor antagonist. J Am Acad Dermatol 2007: 56: 979-988.
39. Togashi Y, Umeuchi H, Okano K et al. Antipruritic activity of the kappa-opioid receptor agonist, TRK-820. Eur J Pharmacol 2002: 435: 259-264.
40. Dawn A G, Yosipovitch G. Butorphanol for treatment of intractable pruritus. J Am Acad Dermatol 2006: 54: 527-531.
41. Wikstrom B, Gellert R, Ladefoged S D et al. {kappa}-Opioid System in Uremic Pruritus: Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Studies. J Am Soc Nephrol 2005: 16: 3742-3747.
42. Slominski A, Tobin D J, Shibahara S, Wortsman J. Melanin pigmentation in mammalian skin and its hormonal regulation. Physiol Rev 2004: 84: 1155-1228.
43. Spencer J D, Gibbons N C, Rokos H, Peters E M, Wood J M, Schallreuter K U. Oxidative stress via hydrogen peroxide affects proopiomelanocortin peptides directly in the epidermis of patients with vitiligo. J Invest Dermatol 2007: 127: 411-420.
44. Park H Y, Wu H, Killoran C E, Gilchrest B A. The receptor for activated C-kinase-I (RACK-I) anchors activated PKC-beta on melanosomes. J Cell Sci 2004: 117: 3659-3668.
45. Tobin D J. Human hair pigmentation-biological aspects. Int J Cosmet Sci 2008: 30: 233-257.
46. Stenn K S, Paus R. Controls of hair follicle cycling. Physiol Rev 2001: 81: 449-494.
47. Park H Y, Lee J, Gonzalez S et al. Topical application of a protein kinase C inhibitor reduces skin and hair pigmentation. J Invest Dermatol 2004: 122: 159-166.
48. Zouboulis C C, Baron J M, Bohm M et al. Frontiers in sebaceous gland biology and pathology. Exp Dermatol 2008: 17: 542-551.
49. Bidlack J M, Khimich M, Parkhill A L, Sumagin S, Sun B, Tipton C M. Opioid receptors and signaling on cells from the immune system. J Neuroimmune Pharmacol 2006: 1: 260-269.
50. Sharp B M. Multiple opioid receptors on immune cells modulate intracellular signaling. Brain Behav Immun 2006: 20: 9-14.
51. Jaume M, Laffont S, Chapey E, Blanpied C, Dietrich G. Opioid receptor blockade increases the number of lymphocytes without altering T cell response in draining lymph nodes in vivo. J Neuroimmunol 2007: 188: 95-102.
52. Borner C, Stumm R, Hollt V, Kraus J. Comparative analysis of mu-opioid receptor expression in immune and neuronal cells. J Neuroimmunol 2007: 188: 56-63.
53. Chen Y L, Law P Y, Loh H H. Nuclear factor kappaB signaling in opioid functions and receptor gene expression. J Neuroimmune Pharmacol 2006: 1: 270-279.
54. Finley M J, Happel C M, Kaminsky D E, Rogers T J. Opioid and nociceptin receptors regulate cytokine and cytokine receptor expression. Cell Immunol 2008: 252: 146-154.
55. Philippe D, Dubuquoy L, Groux H et al. Anti-inflammatory properties of the mu opioid receptor support its use in the treatment of colon inflammation. J Clin Invest 2003: 111: 1329-1338.
56. Clark J D, Shi X, Li X et al. Morphine reduces local cytokine expression and neutrophil infiltration after incision. Mol Pain 2007: 3: 28.
57. Gaveriaux-Ruff C, Matthes H W, Peluso J, Kieffer B L. Abolition of morphine-immunosuppression in mice lacking the mu-opioid receptor gene. Proc Natl Acad Sci USA 1998: 95: 6326-6330.
58. Roy S, Wang J, Gupta S, Charboneau R, Loh H H, Barke R A. Chronic morphine treatment differentiates T helper cells to Th2 effector cells by modulating transcription factors GATA 3 and T-bet. J Neuroimmunol 2004: 147: 78-81.
59. Benamar K, McMenamin M, Geller E B, Chung Y G, Pintar J E, Adler M W. Unresponsiveness of mu-opioid receptor knockout mice to lipopolysaccharide-induced fever. Br J Pharmacol 2005: 144: 1029-1031.
60. Wang J, Charboneau R, Barke R A, Loh H H, Roy S. Mu-opioid receptor mediates chronic restraint stress-induced lymphocyte apoptosis. J Immunol 2002: 169: 3630-3636.
61. Okuyama K, Ohwada K, Sakurada S et al. The distinctive effects of acute and chronic psychological stress on airway inflammation in a murine model of allergic asthma. Allergol Int 2007: 56: 29-35.
62. McCarthy L E, Nitsche J F, Pintar J E, Rogers T J. The delta-opioid receptor participates in T-cell development by promoting negative selection. J Neuroimmunol 2004: 153: 91-98.
63. Gaveriaux-Ruff C, Filliol D, Simonin F, Matthes H W, Kieffer B L. Immunosuppression by delta-opioid antagonist naltrindole: Delta- and triple mu/delta/kappa-opioid receptor knockout mice reveal a nonopioid activity. J Pharmacol Exp Ther 2001: 298: 1193-1198.
64. Gaveriaux-Ruff C, Simonin F, Filliol D, Kieffer B L. Enhanced humoral response in kappa-opioid receptor knockout mice. J Neuroimmunol 2003: 134: 72-81.
65. Refojo D, Kovalovsky D, Young J I et al. Increased splenocyte proliferative response and cytokine production in beta-endorphin-deficient mice. J Neuroimmunol 2002: 131: 126-134.
66. Hook S, Camberis M, Prout M et al. Preproenkephalin is a Th2 cytokine but is not required for Th2 differentiation in vitro. Immunol Cell Biol 1999: 77: 385-390.
67. Nissen J B, Lund M, Stengaard-Pedersen K, Kragballe K. Enkephalin-like immunoreactivity in human skin is found selectively in a fraction of CD68-positive dermal cells: Increase in enkephalin-positive cells in lesional psoriasis. Arch Dermatol Res 1997: 289: 265-271.
68. Benard A, Boue J, Chapey E, Jaume M, Gomes B, Dietrich G. Delta opioid receptors mediate chemotaxis in bone marrow-derived dendritic cells. J Neuroimmunol 2008: 197: 21-28.
69. Rittner H L, Brack A. Leukocytes as mediators of pain and analgesia. Curr Rheumatol Rep 2007: 9: 503-510.
70. Rittner H L, Labuz D, Richter J F et al. CXCR1/2 ligands induce p38 MAPK-dependent translocation and release of opioid peptides from primary granules in vitro and in vivo. Brain Behav Immun 2007: 21: 1021-1032.
71. Rogers T J, Peterson P K. Opioid G protein-coupled receptors: Signals at the crossroads of inflammation. Trends Immunol 2003: 24: 116-121.
72. Liang D, Shi X, Qiao Y, Angst M S, Yeomans D C, Clark J D. Chronic morphine administration enhances nociceptive sensitivity and local cytokine production after incision. Mol Pain 2008: 4: 7.